You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Innovative Approaches in the Fight Against ASCVD: The Latest News in Dyslipidemia

  • Authors: Kausik K. Ray, MD, MPhil, FRCP; Lale Tokgozoglu, MD, FACC, FESC; Anne Tybjærg Hansen, MD, DMSc; Raul D. Santos, MD, MSc, PhD; Ulrich Laufs, MD
  • CPD Released: 9/27/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/27/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for global cardiologists and primary care physicians (PCPs).

The goal of this activity is to update all respective specialists and PCPs on the latest news in dyslipidemia management, lipoprotein(a) [Lp(a)] science, and management of atherosclerotic cardiovascular disease (ASCVD).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest scientific and clinical trial data on lipid-lowering therapies to reduce low-density lipoprotein (LDL) cholesterol
    • Latest scientific and clinical trial data on small interfering RNA therapies to reduce LDL-C
    • Latest scientific and clinical trial data on lipoprotein(a)


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Kausik K. Ray, MD, MPhil, FRCP

    Professor of Public Health
    Honorary Consultant Cardiologist
    Imperial Centre for Cardiovascular Disease Prevention
    Department of Primary Care & Public Health
    Imperial College London
    London, United Kingdom

    Disclosures

    Disclosure: Kausik K. Ray, MD, MPhil, FRCP, has the following relevant financial relationships:
    Advisor or consultant for: Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Kowa; Novartis; Novo Nordisk; Pfizer
    Speaker or a member of a speakers bureau for: Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis; Novo Nordisk; Pfizer; Sanofi
    Grants for clinical research from: Amgen; Daiichi Sankyo; Regeneron
    Stocks, stock options, or bonds from: Pemi31 Therapeutics

  • Lale Tokgozoglu, MD, FACC, FESC

    Professor of Cardiology
    Hacettepe University
    Past-President, European
    Atherosclerosis Society
    Ankara, Turkey

    Disclosures

    Disclosure: Lale Tokgozoglu, MD, FACC, FESC, has the following relevant financial relationships:
    Advisor or consultant for: Abbott; Amgen; Bayer; Merck Sharp & Dohme; Mylan; Novartis; Sanofi
    Speaker or a member of a speakers bureau for: Abbott; Actelion; Amgen; Bayer; Daiichi Sankyo; Merck Sharp & Dohme; Mylan; Novartis; Novo Nordisk; Pfizer; Recordati; Sanofi; Servier
    Grants for clinical research from: Amgen

  • Anne Tybjærg Hansen, MD, DMSc

    Professor, Chief Physician
    Copenhagen University Hospital
    Faculty of Health and Medical Sciences
    University of Copenhagen
    Copenhagen, Denmark

    Disclosures

    Disclosure: Anne Tybjærg Hansen, MD, DMSc, has the following relevant financial relationships:
    Advisor or consultant for: Akcea; AstraZeneca; Draupnir Bio; Novartis; Regeneron; Sanofi; Silence Therapeutics
    Speaker or a member of a speakers bureau for: Akcea; Novartis; Sanofi

  • Raul D. Santos, MD, MSc, PhD

    Associate Professor
    Director Lipid Clinic Heart Institute (InCor) University
    São Paulo Medical School Hospital
    Researcher Hospital Israelita Albert Einstein
    President International Atherosclerosis Society
    São Paulo, Brazil

    Disclosures

    Disclosure: Raul D. Santos, MD, MSc, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Abbott; Amgen; AstraZeneca; Novartis; Novo Nordisk; PTC Therapeutics; Sanofi
    Speaker or a member of a speakers bureau for: Abbott; Amgen; AstraZeneca; EMS Pharmaceuticals; Getz Pharma; Libbs; PTC Therapeutics; Pfizer; Merck; Merck Sharp & Dohme; Novo Nordisk; Novartis; Sanofi
    Grants for clinical research from: Amgen; Kowa; Sanofi

  • Ulrich Laufs, MD

    Professor of Medicine
    Director, Department of Cardiology
    Leipzig University Hospital
    Leipzig, Germany

    Disclosures

    Disclosure: Ulrich Laufs, MD, has the following relevant financial relationships:
    Advisor or consultant for: Amarin; Amgen; Boehringer Ingelheim; Daiichi-Sankyo; Novartis
    Speaker or a member of a speakers bureau for: ABDA; Amarin; Amgen; Ariba; AstraZeneca; Bayer; Berlin-Chemie; BMBF; Boehringer Ingelheim; DACH; Daiichi-Sankyo; Department of Pharmaceutical Technology; DGK; Eli Lilly and Company; EU; i-cor; Medtronik; Merck Sharp & Dohme; Novartis; NovoNordisk; Pfizer; Roche; Sanofi; Servier; SLAK; Stifterverband; Synlab; UdS; UKL; UKS

Editor

  • Ozerk Akgun, MD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Ozerk Akgun, MD, has disclosed no relevant financial relationships.

Content Reviewer

  • Amy Bernard, MS, BSN, RN-BC, CHCP

    Director, Accreditation and Compliance

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Innovative Approaches in the Fight Against ASCVD: The Latest News in Dyslipidemia

Authors: Kausik K. Ray, MD, MPhil, FRCP; Lale Tokgozoglu, MD, FACC, FESC; Anne Tybjærg Hansen, MD, DMSc; Raul D. Santos, MD, MSc, PhD; Ulrich Laufs, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 9/27/2021

Valid for credit through: 9/27/2022

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Innovative Approaches in The Fight Against Atherosclerotic Cardiovascular Disease: The Latest News in Dyslipidemia

Let’s make a nice introduction to this dyslipidemia update program with Dr Ray.
Kausik K. Ray, MD, MPhil, FRCP

Dyslipidemia Guidelines Review

Dr Tokgozoglu shares her expert comments about the recent guideline recommendations.
Lale Tokgozoglu, MD, FACC, FESC

Lipoprotein(a) Update

Dr Hansen is here to refresh your knowledge about Lipoprotein(a).
Anne Tybjærg Hansen, MD, DMSc

Implementation of Recent Data Into Clinical Practice

Dr Santos helps you to position the Lp(a) testing and ASCVD risk assessment into your daily practice.
Raul D. Santos, MD, MSc, PhD

LDL-C Lowering Treatment Modalities Update

Time to review the recent clinical data of LDL-C lowering treatment with Dr Laufs
Ulrich Laufs, MD

Conclusion

Dr Ray wraps up the discussion on dyslipidemia and ASCVD management.
Kausik K. Ray, MD, MPhil, FRCP